Tumor Biology

, Volume 36, Issue 11, pp 8287–8293 | Cite as

Elevated RABEX-5 protein expression predicts poor prognosis in combined small cell lung cancer

  • Fuliang Zhang
  • Meng Zhang
  • Guohua Hu
  • Qiling Cai
  • Tongbai Xu
Research Article
  • 105 Downloads

Abstract

RABEX-5 has been studied in various solid tumors, but its role in combined small cell lung cancer (C-SCLC) remains unknown. This study aimed to investigate the expression, the potential relevance to clinicopathological characters and prognostic significance of RABEX-5 in patients with C-SCLC. Fifty-two C-SCLC patients who received radical surgery were enrolled in our study. The clinicalpathological data and survival time were reviewed. The mRNA and protein expression of RABEX-5 from the paired tumor tissues and adjacent normal tissues were determined, and its relationship with clinicalpathological variables and prognosis was analyzed. Univariate and multivariate analyses were performed to investigate the prognostic significance of RABEX-5 for C-SCLC. The mRNA and protein expression level of RABEX-5 was significantly elevated in C-SCLC tissues. The increased RABEX-5 protein expression was correlated with clinical stage (p = 0.011) and tumor recurrence (p = 0.006). The median OS and DFS was significantly shorter in the high RABEX-5 expression group compared to low RABEX-5 expression group (OS: 12.0 vs. 21.7 months, p = 0.014; DFS: 6.7 vs. 11.8 months, p = 0.005). Multivariate Cox analysis indicated that high RABEX-5 protein expression was an independent prognostic factor for OS and DFS (p < 0.001). RABEX-5 is a potential useful indicator and predicts a poor long-term prognosis for C-SCLC, which should be considered in defining the prognosis with other well-known prognosticators in C-SCLC patients.

Keywords

Combined small cell lung cancer RABEX-5 Prognosis 

Notes

Conflicts of interest

None.

References

  1. 1.
    Adelstein DJ, Tomashefski Jr JF, Snow NJ, Horrigan TP, Hines JD. Mixed small cell and non-small cell lung cancer. Chest. 1986;89:699–704.CrossRefPubMedGoogle Scholar
  2. 2.
    Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Combined small-cell and non-small-cell lung cancer. J Clin Oncol. 1989;7:607–12.CrossRefPubMedGoogle Scholar
  3. 3.
    Fushimi H, Kikui M, Morino H, Yamamoto S, Tateishi R, Wada A, et al. Histologic changes in small cell lung carcinoma after treatment. Cancer. 1996;77:278–83.CrossRefPubMedGoogle Scholar
  4. 4.
    Radice PA, Matthews MJ, Ihde DC, Gazdar AF, Carney DN, Bunn PA, et al. The clinical behavior of “mixed” small cell/large cell bronchogenic carcinoma compared to “pure” small cell subtypes. Cancer. 1982;50:2894–902.CrossRefPubMedGoogle Scholar
  5. 5.
    Hage R, Elbers JR, Brutel de la Riviere A, van den Bosch JM. Surgery for combined type small cell lung carcinoma. Thorax. 1998;53:450–3.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Weng CT, Chu PY, Liu MT, Chen MK. Small cell carcinoma of the head and neck: a single institution’s experience and review of the literature. J Otolaryngol Head Neck Surg. 2008;37:788–93.PubMedGoogle Scholar
  7. 7.
    Wong YN, Jack RH, Mak V, Henrik M, Davies EA. The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970–2004. BMC Cancer. 2009;9:209.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Babakoohi S, Fu P, Yang M, Linden PA, Dowlati A. Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer. 2013;14:113–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models. J Exp Clin Cancer Res. 2014;33:111.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zhan P, Wang Q, Qian Q, Wei SZ, Yu LK. CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review. J Exp Clin Cancer Res. 2011;30:99.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Zhu H, Zhu G, Liu J, Liang Z, Zhang XC, Li G. Rabaptin-5-independent membrane targeting and Rab5 activation by RABEX-5 in the cell. Mol Biol Cell. 2007;18:4119–28.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zhang X, Min J, Wang Y, Li Y, Li H, Liu Q, et al. RABEX-5 plays an oncogenic role in breast cancer by activating MMP-9 pathway. J Exp Clin Cancer Res. 2013;32:52.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wang S, Lu A, Chen X, Wei L, Ding J. RABEX-5 is upregulated and plays an oncogenic role in gastric cancer development by activating the VEGF signaling pathway. PLoS One. 2014;9:e113891.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhang H, Cheng S, Wang A, Ma H, Yao B, Qi C, et al. Expression of RABEX-5 and its clinical significance in prostate cancer. J Exp Clin Cancer Res. 2014;33:31.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Nimmrich I, Erdmann S, Melchers U, Finke U, Hentsch S, Moyer MP, et al. Seven genes that are differentially transcribed in colorectal tumor cell lines. Cancer Lett. 2000;160:37–43.CrossRefPubMedGoogle Scholar
  16. 16.
    Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, Hida T, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res. 2008;14:6092–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Nicholson SA, Beasley MB, Brambilla E, Hasleton PS, Colby TV, Sheppard MN, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184–97.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang X, Jiang R, Li K. Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer. Cell Biochem Biophys. 2014;69:633–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Wan J, Ma J, Mei J, Shan G. The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells. J Exp Clin Cancer Res. 2009;28:150.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Huang J, Song H, Liu B, Yu B, Wang R, Chen L. Expression of Notch-1 and its clinical significance in different histological subtypes of human lung adenocarcinoma. J Exp Clin Cancer Res. 2013;32:84.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hu H, Milstein M, Bliss JM, Thai M, Malhotra G, Huynh LC, et al. Integration of transforming growth factor beta and RAS signaling silences a RAB5 guanine nucleotide exchange factor and enhances growth factor-directed cell migration. Mol Cell Biol. 2008;28:1573–83.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Fuliang Zhang
    • 1
  • Meng Zhang
    • 2
  • Guohua Hu
    • 1
  • Qiling Cai
    • 1
  • Tongbai Xu
    • 1
  1. 1.Department of Respiratory Medicine, Tianjin Hospital of ITCWMNankai HospitalTianjinChina
  2. 2.Department of ICUFirst Teaching Hospital of Tianjin University of TCMTianjinChina

Personalised recommendations